Cargando…

Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression

With the major advances in cancer immunology and immunotherapy, it is critical to consider that most immune cells are short-lived and need to be continuously replenished from hematopoietic stem and progenitor cells. Hematologic abnormalities are prevalent in cancer patients, and many ground-breaking...

Descripción completa

Detalles Bibliográficos
Autores principales: Plackoska, Viktoria, Shaban, Dania, Nijnik, Anastasia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763314/
https://www.ncbi.nlm.nih.gov/pubmed/36561751
http://dx.doi.org/10.3389/fimmu.2022.1041010
_version_ 1784853030505545728
author Plackoska, Viktoria
Shaban, Dania
Nijnik, Anastasia
author_facet Plackoska, Viktoria
Shaban, Dania
Nijnik, Anastasia
author_sort Plackoska, Viktoria
collection PubMed
description With the major advances in cancer immunology and immunotherapy, it is critical to consider that most immune cells are short-lived and need to be continuously replenished from hematopoietic stem and progenitor cells. Hematologic abnormalities are prevalent in cancer patients, and many ground-breaking studies over the past decade provide insights into their underlying cellular and molecular mechanisms. Such studies demonstrate that the dysfunction of hematopoiesis is more than a side-effect of cancer pathology, but an important systemic feature of cancer disease. Here we review these many advances, covering the cancer-associated phenotypes of hematopoietic stem and progenitor cells, the dysfunction of myelopoiesis and erythropoiesis, the importance of extramedullary hematopoiesis in cancer disease, and the developmental origins of tumor associated macrophages. We address the roles of many secreted mediators, signaling pathways, and transcriptional and epigenetic mechanisms that mediate such hematopoietic dysfunction. Furthermore, we discuss the important contribution of the hematopoietic dysfunction to cancer immunosuppression, the possible avenues for therapeutic intervention, and highlight the unanswered questions and directions for future work. Overall, hematopoietic dysfunction is established as an active component of the cancer disease mechanisms and an important target for therapeutic intervention.
format Online
Article
Text
id pubmed-9763314
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97633142022-12-21 Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression Plackoska, Viktoria Shaban, Dania Nijnik, Anastasia Front Immunol Immunology With the major advances in cancer immunology and immunotherapy, it is critical to consider that most immune cells are short-lived and need to be continuously replenished from hematopoietic stem and progenitor cells. Hematologic abnormalities are prevalent in cancer patients, and many ground-breaking studies over the past decade provide insights into their underlying cellular and molecular mechanisms. Such studies demonstrate that the dysfunction of hematopoiesis is more than a side-effect of cancer pathology, but an important systemic feature of cancer disease. Here we review these many advances, covering the cancer-associated phenotypes of hematopoietic stem and progenitor cells, the dysfunction of myelopoiesis and erythropoiesis, the importance of extramedullary hematopoiesis in cancer disease, and the developmental origins of tumor associated macrophages. We address the roles of many secreted mediators, signaling pathways, and transcriptional and epigenetic mechanisms that mediate such hematopoietic dysfunction. Furthermore, we discuss the important contribution of the hematopoietic dysfunction to cancer immunosuppression, the possible avenues for therapeutic intervention, and highlight the unanswered questions and directions for future work. Overall, hematopoietic dysfunction is established as an active component of the cancer disease mechanisms and an important target for therapeutic intervention. Frontiers Media S.A. 2022-12-06 /pmc/articles/PMC9763314/ /pubmed/36561751 http://dx.doi.org/10.3389/fimmu.2022.1041010 Text en Copyright © 2022 Plackoska, Shaban and Nijnik https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Plackoska, Viktoria
Shaban, Dania
Nijnik, Anastasia
Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression
title Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression
title_full Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression
title_fullStr Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression
title_full_unstemmed Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression
title_short Hematologic dysfunction in cancer: Mechanisms, effects on antitumor immunity, and roles in disease progression
title_sort hematologic dysfunction in cancer: mechanisms, effects on antitumor immunity, and roles in disease progression
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763314/
https://www.ncbi.nlm.nih.gov/pubmed/36561751
http://dx.doi.org/10.3389/fimmu.2022.1041010
work_keys_str_mv AT plackoskaviktoria hematologicdysfunctionincancermechanismseffectsonantitumorimmunityandrolesindiseaseprogression
AT shabandania hematologicdysfunctionincancermechanismseffectsonantitumorimmunityandrolesindiseaseprogression
AT nijnikanastasia hematologicdysfunctionincancermechanismseffectsonantitumorimmunityandrolesindiseaseprogression